Journal profile · Biochemistry, Genetics and Molecular Biology-Developmental Biology
Clinical Epigenetics
ISSN 1868-7075 · eISSN 1868-7083 · BioMed Central · Germany · Founded 2010
Clinical Epigenetics: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 5.68; fully open access; APC about USD 3,890; median 135 days to acceptance (99 articles, last 24 months); 232 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Clinical Epigenetics is published by BioMed Central and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Epigenetics and DNA Methylation, Genetic Syndromes and Imprinting and Genetic Associations and Epidemiology, together about 49.8% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Encompassing the broad spectrum of epigenetics research from basic research to innovations in therapeutic treatments, Clinical Epigenetics is a top tier, open access journal devoted to the study of epigenetic principles and mechanisms as applied to human development, disease, diagnosis and treatment. The journal particularly welcomes submissions involving clinical trials, translational research, new and innovative methodologies and model organisms providing mechanistic insights. The journal is divided into the following sections: Aging and development epigenetics Allergy, immunology, and pathogen epigenetics Cancer epigenetics and diagnostics Cardiovascular epigenetics Endocrinology and metabolic epigenetics Environmental epigenetics Epigenetic biomarkers Epigenetic technologies Epigenetic Drugs, Trials and Therapy Innovative therapies Lifestyle epigenetics Neurology and psychiatry epigenetics Regenerative medicine Reproductive and transgenerational epigenetics Please read the Sections' descriptions to know more about the journal's aims and scope. Clinical Epigenetics follows two specific editorial policies: - Editorial Policy Regarding Submissions Focusing on Non-coding RNAs or RNA Modifications - Editorial Policy Regarding Submissions Focusing on Reanalysis of Publicly Available Data and In Silico Approaches Please review these policies in detail before submitting your manuscript to the journal: https://link.springer.com/journal/13148/updates/27797032
From the journal's Aims & Scope
Research area (LetPub): Biochemistry, Genetics and Molecular Biology-Developmental Biology
Editor-in-chief Lucia AltucciPublisher website
Editorial board by country: 5 in mainland China (about 3%); most named United States 36, Italy 20, United Kingdom 17, Germany 13, Australia 10 (174 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology40.2%
- Genetic Syndromes and ImprintingBiochemistry, Genetics and Molecular Biology5.4%
- Genetic Associations and EpidemiologyBiochemistry, Genetics and Molecular Biology4.2%
- Histone Deacetylase Inhibitors ResearchBiochemistry, Genetics and Molecular Biology4.2%
- Cancer-related gene regulationBiochemistry, Genetics and Molecular Biology4%
- Birth, Development, and HealthMedicine3.8%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology3.6%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology3.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Genetics & Heredity | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
| Minor | Genetics & Heredity | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Genetics & Heredity | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASPublisher website
Other: Google Scholar, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 5.68LetPub ·
- Impact factor (publisher) 2025
- 5.7Publisher website ·
- 5-year impact factor (publisher) 2025
- 6Publisher website ·
- CiteScore 2026-06
- 8.1LetPub ·
- SJR 2026-06
- 1.79LetPub ·
- SNIP 2026-06
- 1.09LetPub ·
- h-index
- 117OpenAlex ·
- i10-index
- 1,600OpenAlex ·
- 2-year mean citedness
- 5.54OpenAlex ·
- Self-citation rate
- 3.5%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 227LetPub ·
- Downloads per year (publisher) 2025
- 2,400,000Publisher website ·
Articles by year OpenAlex count · 2,371 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 206 | 206 | 81 |
| 2025 | 232 | 232 | 1,116 |
| 2024 | 194 | 194 | 2,302 |
| 2023 | 197 | 197 | 3,460 |
| 2022 | 196 | 196 | 4,407 |
| 2021 | 234 | 234 | 8,687 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
135 daysMedian, submission to acceptance · P25–P75 88 days – 224 days
- Acceptance to online
- median 17 days (99 articles)
- Submission to online
- median 180 days
- Sample
- 99 articles with submission and acceptance dates (450 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 12 weeksLetPub ·
- Submission to first decision
- 7 daysPublisher website ·
- Peer review
- Anonymous peer reviewLetPub
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,890 / EUR 3,190 / GBP 2,790 | — | — | |
| LetPub | GBP 2,490 / USD 3,390 / EUR 2,890 | Yes | — | |
| Publisher website | GBP 2,790 / USD 3,890 / EUR 3,190 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers1, by deadline
Publisher websiteWhat to prepare2 items from the author guidelines
- Reference style
- Vancouver
- Suggested reviewers
- Optional
Article types accepted6
- brief reportFormatting guidelines for specific article types can be found below. Research Review Methodology Brief report Correspondence HypothesisLength not stated
- correspondenceFormatting guidelines for specific article types can be found below. Research Review Methodology Brief report Correspondence HypothesisLength not stated
- hypothesisFormatting guidelines for specific article types can be found below. Research Review Methodology Brief report Correspondence HypothesisLength not stated
- methodologyFormatting guidelines for specific article types can be found below. Research Review Methodology Brief report Correspondence HypothesisLength not stated
- researchFormatting guidelines for specific article types can be found below. Research Review Methodology Brief report Correspondence HypothesisLength not stated
- reviewFormatting guidelines for specific article types can be found below. Research Review Methodology Brief report Correspondence HypothesisLength not stated
Policy excerpts from the journal's websiteData availability, License & copyright, Open access, Peer review
- Data availability Formatting the 'Availability of data and materials' section of your manuscript
The following format for the 'Availability of data and materials section of your manuscript should be used:
Source ↗Publisher website ·- License & copyright Licensing and copyright
Creative Commons licences Open access articles in Springer Nature journals are published under Creative Commons licences. These provide an industry-standard framework to support easy re-use of open access material. Under Creative Commons licences, authors retain copyright of their articles. Clinical Epigenetics articles are published open access under a CC BY-NC-ND (Creative Commons Attribution No…
Source ↗Publisher website ·- Open access Benefits of open access
Publishing open access (OA) offers a number of benefits, including greater reach and readership for your work: Cited more 1.6x more citations of OA articles than non-OA articles across all subjects Downloaded more 4x more downloads of OA articles than non-OA articles Greater impact 2.5x more Altmetric attention. OA articles attracted 1.9x more news mentions and 1.2x more policy mentions Open acces…
Source ↗Publisher website ·- Peer review Peer review policy
Editorial Policy Regarding Submissions Focusing on Non-coding RNAs or RNA Modifications Model summary
Peer review is the process used to evaluate the quality of a manuscript before publication. Independent researchers in the relevant field assess submitted manuscripts to check their validity and robustness. Their feedback guides editors in making publication decisions. Typically, two or more experts evaluate each manuscript based on three main criteria: scientific robustness: is the research metho…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- BioMed Central
- Country or region
- Germany
- Language
- English
- Founded
- 2010
- ISSN
- 1868-7075
- Electronic ISSN
- 1868-7083
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- Peer review process ↗LetPub
- Editorial board ↗LetPub
FAQ
Frequently asked questions about Clinical Epigenetics
What CAS zone is Clinical Epigenetics in?
In the 2025 upgraded edition of the CAS Journal Ranking, Clinical Epigenetics is in Zone 2 of Medicine, and in Zone 2 of the minor category Genetics & Heredity / Oncology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Clinical Epigenetics?
The latest impact factor listed by LetPub is 5.68; CiteScore 8.1, h-index 117.
How long does peer review take at Clinical Epigenetics?
Based on the dates recorded on 99 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 135 days (interquartile range 88–224 days); authors report an average review time of about 12 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Clinical Epigenetics?
According to the journal's author guidelines: Reference style: Vancouver; Suggested reviewers: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Clinical Epigenetics based?
Of the 174 board members whose country the journal's board page names, 5 (about 3%) are in mainland China; the countries named most often are United States (36), Italy (20) and United Kingdom (17). Counted from the institutions listed on the board page; for reference only.
Which databases index Clinical Epigenetics?
According to LetPub and DOAJ records, Clinical Epigenetics is indexed in SCIE, Scopus and DOAJ. The journal's website also lists MEDLINE, Embase and CAS; that list has not been checked against each database.
Is Clinical Epigenetics open access, and what is the APC?
Clinical Epigenetics is a fully open-access journal. APC about USD 3,890.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .